The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

MARCH 4, 2021

. “For patients who suffer from alopecia areata, it is not a cosmetic condition, it is a devastating autoimmune disease that can have significant psychological effects. vice president of immunology development at Lilly. ” Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. .

Trials 52

Trials Development Dermatology Clinical Trials 52

The Pharma Data

NOVEMBER 4, 2020

Key findings of the research showed that patients with alopecia areata suffer significantly increased burden of illness, including a negative impact on many aspects of daily life, extending considerably beyond the cosmetic concerns of hair loss. License and research and development revenue.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Dermatology 52

XTalks

AUGUST 2, 2023

Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment. This partnership will expand the company’s immunology pipeline. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98